Celldex Therapeutics Inc (CLDX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.26B
Last updated: Nov 17, 2026 at 11:05 AM ET
Celldex Therapeutics Inc (CLDX) Stock Forecast
Analysts expect Celldex Therapeutics (CLDX) to earn -$4.02 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.37M. Of 15 analysts, 14 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$4.19.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.93, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 13.3% |
| Buy | 12 | 80.0% |
| Hold | 1 | 6.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 383.2%.
- Fiscal year ending Dec 31, 2026
- -$4.02
- EPS consensus, revenue $1.37M
- Fiscal year ending Dec 31, 2027
- -$4.19
- EPS consensus, revenue $6.62M
- Next report
- Feb 23, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.02 | -$4.14 to -$3.65 | 8 | $1.37M | N/A | 10 |
| Dec 31, 2027 | -$4.19 | -$4.87 to -$3.47 | 10 | $6.62M | N/A | 10 |
Quarterly Estimates
The EPS consensus rises from -$1.06 for the quarter ending Dec 31, 2026 to -$0.97 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.06 | -$1.10 to -$0.97 | 15 | $1.73M | N/A | 13 |
| Mar 31, 2027 | -$0.97 | -$1.14 to -$0.81 | 5 | $250000 | N/A | 4 |
Estimate Revisions
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2027 | 0 | 2 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$4.11.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.02 | -$4.12 | -$4.12 | -$4.12 | -$4.11 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.19 | -$4.25 | -$4.24 | -$4.21 | -$4.16 | N/A |
| Quarter ending Mar 31, 2027 | -$0.97 | -$0.91 | -$0.91 | -$0.91 | -$0.91 | N/A |
Frequently Asked Questions About CLDX
What is the CLDX stock forecast?
Consensus analyst estimates put Celldex Therapeutics's EPS at -$4.02 for the fiscal year ending Dec 31, 2026, on revenue of $1.37M. The consensus rating from 15 analysts is Buy.
How do analysts rate CLDX stock?
Of 15 analysts covering Celldex Therapeutics, 2 rate it Strong Buy, 12 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CLDX next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.02, with estimates from -$4.14 to -$3.65 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.19, with estimates from -$4.87 to -$3.47 from 10 analysts.
What revenue do analysts expect from Celldex Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.37M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.62M.
How many analysts cover CLDX?
15 analysts rate Celldex Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CLDX pages: Overview, Earnings, Forecast, Financials, Competitors